Skip to content
Calculator
Evidence: MediumPeptideIn Clinical Trials17-amino-acid peptideInvestigational · phase 3Prostate enlargement

Fexapotide

A single prostate injection designed to shrink the gland

Fexapotide triflutate is a synthetic 17-amino-acid peptide that is injected once into the prostate, through the rectum under ultrasound guidance, in a clinic visit lasting minutes. It makes prostate gland cells die by apoptosis. Long-term follow-up of two placebo-controlled phase 3 trials reported fewer surgeries and urinary retention episodes in men with benign prostatic hyperplasia. It is not approved.

Used in human trials: 2.5 mg, Single injection, with open-label re-injection in crossover, Transrectal injection into the prostate (Phase 3: benign prostatic hyperplasia (995 men, double-blind)) Details ↓

Overview

What is it?

Benign prostatic hyperplasia, the non-cancerous enlargement of the prostate, causes urinary symptoms in many older men. Treatment usually starts with daily tablets and can end in surgery. Fexapotide was developed by Nymox as a third option: a single injection into the gland itself. In rats, injected fexapotide caused prostate glandular cells to die by apoptosis within one to three days and led to near-total loss of glandular tissue by six to twelve months, without damaging the nerves, vessels or connective tissue around them.

The main human evidence is two placebo-controlled, double-blind phase 3 trials in 995 men at 72 US sites, randomised 3 to 2 to fexapotide 2.5 mg or placebo, with follow-up of 2 to 6.75 years. The published report gives long-term results: symptom scores improved more with fexapotide (median 5.2 against 3.0 points), acute urinary retention and later prostate cancer were less frequent, and men who crossed over to fexapotide needed surgery less often than those who switched to tablets (8.1% against 27.9% at three years). Safety did not differ from placebo. The abstract does not state the 12-month primary endpoint result.

The same injection was tested in Grade Group 1 prostate cancer, the lowest-risk form usually managed by watching it. In 146 men randomised to 2.5 mg, 15 mg or active surveillance, a single injection reduced progression to treatment over four years, more so at 15 mg, with no drug-related serious adverse events.

Several authors of these trials disclosed consulting for, or shares in, Nymox. A 2014 independent review judged the treatment experimental on small numbers. Fexapotide has not been approved.

2.5 mg
Single injection in the phase 3 trials
995 men with BPH · PMID 29380128
-5.2 vs -3.0
Median long-term symptom score change
fexapotide against placebo · PMID 29380128
371
Rats in the safety study
glandular apoptosis within 24-72 hours · PMID 31909043
Science

Mechanism of Action

Fexapotide triflutate (NX-1207), developed by Nymox, is a peptide injected once into the prostate, where it triggers the programmed death of glandular cells.

🎯

Glandular cell death

In 371 rats, injected into the prostate it caused apoptosis of glandular cells within 24 to 72 hours and near-total loss of the glandular epithelium by 6 to 12 months.

💉

A one-off local treatment

It is given as a single injection into the prostate through the rectum rather than as daily tablets; in the 995-man phase 3 programme it showed no significant safety differences from placebo.

Evidence

Published Research

Studies of fexapotide, from their PubMed abstracts: the randomised trials, the rat ablation work and the reviews written at each stage of its development. The many reviews of the wider prostate treatment landscape that mention it in passing are listed rather than carded.

Human2018

Long-term phase 3 BPH trials

In 995 men (3:2 fexapotide 2.5 mg:placebo; follow-up mean 3.58 years), long-term symptom improvement was greater (median -5.2 vs -3.0, p < 0.0001); acute urinary retention and prostate cancer incidence were lower; BPH intervention at 3 years was 8.08% vs 27.85% for oral medication crossover; no significant safety differences.

PMID: 29380128
Human2020

Grade Group 1 prostate cancer

In 146 men randomised to 2.5 mg, 15 mg or active surveillance, a single injection significantly reduced progression to intervention over 4 years, with 15 mg superior to 2.5 mg and no drug-related serious adverse events.

PMID: 32088746
Animal2019

Selective ablation in rats

In 371 rats, intraprostatic fexapotide caused glandular cell apoptosis within 24-72 hours and near-total loss of glandular epithelium at 6-12 months, sparing periprostatic nerves, vessels and stroma.

PMID: 31909043
Review2019

Review of the trial programme

More than 1,700 fexapotide and control injections in randomised blinded trials were reviewed; long-term US studies reported symptom improvement and fewer retention episodes and surgeries; all three authors disclosed Nymox consulting.

PMID: 30719081
Review2014

Independent evidence review

NX1207 reduced prostate volume and improved symptoms, but patient numbers were still low and treatment was still experimental.

PMID: 25157337
Review2022

Cost-effectiveness model

A Medicare-perspective model found fexapotide about as cost-effective as initial tablets at up to $14,000 per injection with a $150,000 per QALY threshold; one author disclosed Nymox consulting and shares.

PMID: 35550071
Review2010

The drug as it looked in 2010

An early review of NX-1207 described symptomatic improvement substantially better than the BPH drugs approved at the time, with no significant safety problems, and noted that larger phase 3 trials were under way. Written before those trials reported.

PMID: 20050813
Review2011

An update for clinicians

A 2011 update on NX-1207's potential in benign prostatic hyperplasia, written for clinicians while the phase 3 programme was still running.

PMID: 23251763
Review2018

A commentary on the long-term trials

A urologist's commentary on the published long-term safety and efficacy trials of fexapotide triflutate for symptomatic prostate enlargement.

PMID: 30412936
Dosing

Dosing Data

The amounts below are the single injections given in fexapotide's published trials.

These are trial amounts given by urologists under study protocols, not recommendations. See a doctor before using any peptide.
ProtocolDoseFrequencyDurationRoute
Phase 3: benign prostatic hyperplasia (995 men, double-blind) Human studyPMID 293801282.5 mgSingle injection, with open-label re-injection in crossoverFollow-up mean 3.58 yearsTransrectal injection into the prostate
Grade Group 1 prostate cancer (146 men, randomised) Human studyPMID 320887462.5 mg or 15 mgSingle injection4-year follow-upTransrectal injection into the prostate

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Single injections
Fexapotide was given as one 2.5 mg or 15 mg injection into the prostate; there is no weight-based calculation.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Fexapotide is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: transrectal injection into the prostate). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.

Source: the route and amount of each dose row in Dosing Data below.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Fexapotide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Fexapotide stays intact once mixed.

How it is taken

As it was given in human studies: Transrectal injection into the prostate (Single injection, with open-label re-injection in crossover; Phase 3: benign prostatic hyperplasia (995 men, double-blind)).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Phase 3: benign prostatic hyperplasia (995 men, double-blind): Follow-up mean 3.58 years; Grade Group 1 prostate cancer (146 men, randomised): 4-year follow-up.

When effects appear: unknown; no source on this page gives a time to effect for Fexapotide. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: No significant safety differences from placebo in the long-term BPH trials; No drug-related serious adverse events in the prostate cancer trial. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Fexapotide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the trials above”).

Interactions

Unknown: a PubMed search for human interaction studies of Fexapotide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Fexapotide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Fexapotide's expected mass, 2,055.5 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: In Clinical Trials (Not approved). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the trials above.

● No significant safety differences from placebo in the long-term BPH trials
● No drug-related serious adverse events in the prostate cancer trial

Contraindications & Cautions

There is no label.

● Not approved for any use
Questions

Frequently Asked Questions

?What is fexapotide?

An investigational 17-amino-acid peptide injected once into the prostate under ultrasound guidance. It causes prostate gland cells to die, aiming to shrink an enlarged prostate.

?Does fexapotide work for an enlarged prostate?

Long-term follow-up of two placebo-controlled phase 3 trials reported better symptom scores and fewer surgeries and urinary retention episodes. The trials involved investigators with financial ties to the developer, and the 12-month primary result is not given in the published abstract.

?Is fexapotide approved?

No. It has no FDA approval in Drugs@FDA as of October 3, 2026.

?Is it used for prostate cancer?

It was tested in Grade Group 1 prostate cancer, where a single injection reduced progression to treatment over four years compared with active surveillance. It is not approved for that either.

Bibliography

References

  1. [other] PubChem CID 16207730, Fexapotide: formula C90H163N27O25S, molecular weight 2055.5. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/16207730
  2. [fda] FDA. Drugs@FDA (openFDA): no application on record for fexapotide. Read October 3, 2026.
  3. [registry] ClinicalTrials.gov API v2, read October 3, 2026: NCT00918983 and NCT00945490 (phase 3 BPH, 500 each, completed), NCT01438775 and NCT01846793 (phase 3 re-injection, 192 and 160, completed), NCT02003742 (phase 3, 104, terminated), NCT01620515 (phase 2 low-risk prostate cancer, 141, completed).
  4. [clinical-trial] Shore N, et al. "Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement." World J Urol, 2018;36(5):801-809. PMID: 29380128.
  5. [clinical-trial] Shore N, et al. "Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results." World J Urol, 2020;38(12):3101-3111. PMID: 32088746.
  6. [pubmed] Averback P, et al. "Fexapotide Triflutate Induces Selective Prostate Glandular Pharmaco-Ablation in the Rat." Res Rep Urol, 2019;11:343-350. PMID: 31909043.
  7. [pubmed] Shore N, et al. "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia." Ther Adv Urol, 2019;11:1756287218820807. PMID: 30719081.
  8. [pubmed] Kunit T, et al. "An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia." Res Rep Urol, 2014;6:67-70. PMID: 25157337.
  9. [pubmed] Wei Y, et al. "Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis." BMC Urol, 2022;22(1):76. PMID: 35550071.
  10. [pubmed] Shore N. "NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia." Expert Opin Investig Drugs, 2010;19(2):305-10. PMID: 20050813.
  11. [pubmed] Shore N, et al. "The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians." Ther Adv Chronic Dis, 2011;2(6):377-83. PMID: 23251763.
  12. [pubmed] Kaplan SA. "Re: Fexapotide Triflutate: Results of Long-Term Safety and Efficacy Trials of a Novel Injectable Therapy for Symptomatic Prostate Enlargement." J Urol, 2018;200(3):473-474. PMID: 30412936.
  13. [pubmed] Bayés M, et al. "Gateways to clinical trials." Methods Find Exp Clin Pharmacol, 2005;27(3):193-219. PMID: 15834452.
  14. [pubmed] Hashim H, et al. "Emerging drugs for the treatment of benign prostatic obstruction." Expert Opin Emerg Drugs, 2010;15(2):159-74. PMID: 20446824.
  15. [pubmed] Arenas da Silva LF, et al. "[New treatment strategies for male lower urinary tract symptoms]." Urologe A, 2012;51(12):1697-702. PMID: 23139025.
  16. [pubmed] Bschleipfer T, et al. "[Intraprostatic injection therapy in patients with benign prostatic syndrome]." Urologe A, 2013;52(3):354-8. PMID: 23435646.
  17. [pubmed] Andersson KE. "Treatment of lower urinary tract symptoms: agents for intraprostatic injection." Scand J Urol, 2013;47(2):83-90. PMID: 23281591.
  18. [pubmed] Lusuardi L, et al. "New emerging technologies in benign prostatic hyperplasia." Curr Opin Urol, 2013;23(1):25-9. PMID: 23138466.
  19. [pubmed] Russo A, et al. "Latest pharmacotherapy options for benign prostatic hyperplasia." Expert Opin Pharmacother, 2014;15(16):2319-28. PMID: 25164497.
  20. [pubmed] Füllhase C, et al. "New strategies in treating male lower urinary tract symptoms." Curr Opin Urol, 2014;24(1):29-35. PMID: 24285261.
  21. [pubmed] Chung A, et al. "What's truly minimally invasive in benign prostatic hyperplasia surgery?." Curr Opin Urol, 2014;24(1):36-41. PMID: 24247171.
  22. [pubmed] Nair SM, et al. "Evolving and investigational therapies for benign prostatic hyperplasia." Can J Urol, 2015;22 Suppl 1:82-7. PMID: 26497348.
  23. [pubmed] Magistro G, et al. "New intraprostatic injectables and prostatic urethral lift for male LUTS." Nat Rev Urol, 2015;12(8):461-71. PMID: 26195444.
  24. [pubmed] Andersson KE. "Intraprostatic injections for lower urinary tract symptoms treatment." Curr Opin Urol, 2015;25(1):12-8. PMID: 25333915.
  25. [pubmed] Ebbing J, et al. "Anesthesia-free procedures for benign prostate obstruction: worth it?." Curr Opin Urol, 2015;25(1):32-9. PMID: 25340879.
  26. [pubmed] Magistro G, et al. "[Minimally invasive treatment of benign prostatic hyperplasia]." Urologe A, 2016;55(11):1419-1432. PMID: 27761589.
  27. [pubmed] Magistro G, et al. "Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms." Eur Urol, 2017;72(6):986-997. PMID: 28734706.
  28. [pubmed] Lombardo R, et al. "Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment." Minerva Urol Nefrol, 2018;70(6):570-578. PMID: 30298711.
  29. [pubmed] Chung ASJ, et al. "Update on minimally invasive surgery and benign prostatic hyperplasia." Asian J Urol, 2018;5(1):22-27. PMID: 29379732.
  30. [pubmed] Magistro G, et al. "[Novel minimally invasive treatment options for male lower urinary tract symptom]." Urologe A, 2019;58(3):254-262. PMID: 30790004.
  31. [pubmed] Ückert S, et al. "Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate." World J Urol, 2020;38(6):1423-1435. PMID: 31506747.
  32. [pubmed] Ng BHS, et al. "A state-of-art review on the preservation of sexual function among various minimally invasive surgical treatments for benign prostatic hyperplasia: Impact on erectile and ejaculatory domains." Investig Clin Urol, 2021;62(2):148-158. PMID: 33660441.
  33. [pubmed] Franz J, et al. "[Minimally Invasive Therapy: What Is The Status In 2021 - What's Coming, What's Going?]." Aktuelle Urol, 2022;53(3):231-239. PMID: 35231939.
  34. [pubmed] Matsukawa A, et al. "Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis." Eur Urol Oncol, 2024;7(3):376-400. PMID: 38277189.

Sources & Citations

Studies were read from their PubMed records and trial registrations from ClinicalTrials.gov, October 3, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-19